pcos-2018-posters-accepted-abstracts

24 / 25

PCOS 2018 Journal of Clinical and Molecular Endocrinology
ISSN: 2572-5432 Page 52
June 07-08, 2018
London, UK
4th World Congress on
Polycystic Ovarian
Syndrome
Background: Polycystic ovary syndrome (PCOS) affects 10%–
15% females of reproductive age. Insulin resistance is a central
feature of PCOS. Hyperinsulinemia contributes to anovulation,
hyper androgenism, infertility and early pregnancy loss along
with increased risks of diabetes and cardiovascular events in
women with PCOS. Furocyst (furostanolic saponins) ameliorates
the metabolic syndrome associated with insulin resistance
in PCOS and prevents long-term cardiovascular and diabetes
complications. Based on the published study of Furocyst and
three patents (US Patent 8217165B2 July 10, 2012, US Patent
8754205B2 June 17, 2014, Europe Patent 2285821 B1 December
17, 2014) this observation study was planned.
Objective: Our specific objective was to evaluate reduction in
ovary volume and insulin resistance in women with PCOS, treated
with furostanolic saponins (Furocyst).
Method: An open-labeled, single armed and non-comparative
observation study on 30 female subjects suffering from PCOS
with high insulin resistance was conducted. Patients were
enrolled as per inclusion, i.e. premenopausal women between
18–45 years diagnosed with PCOS with adequate hepatic, renal
and hematological functions. Patients with Cushing’s syndrome/
androgen secreting tumor/thyroid-dysfunction were excluded.
Included subjects received Furocyst and were assessed on
various parameters on second day of the cycle in the beginning,
and then after every four weeks within a treatment period of 12
weeks. Ovary volume was calculated with lower abdomen USG/
TVS and Insulin resistance was calculated by HOMA-IR method.
Conclusion: After 12 weeks of Furocyst intake, a significant
reduction in ovary volume, insulin resistance and LH:FSH ratio
was observed. The reduction in left and right ovary volume was
24.35% and 25.97%, respectively (p<0.001). Reduction in insulin
resistance and fasting insulin was also found highly significant
(p=.002 and .007). The reduction in fetal bovine serum (FBS)
and LH was also found to be highly significant (p<.001). After
treatment with Furocyst, the irregularity of menstrual cycle
was also significantly reduced (p<.001). No significant adverse
effects were observed. In summary, Furocyst was efficacious in
ameliorating the symptoms of PCOS.
Efficacy evaluation of furostanolic saponins (Furocyst) in
management of insulin resistance and ovary volume in PCOS
subjects
Priti Kumar1, Kiran Tiwari2 and Gopesh Lamgora2
1Sunflower Medical Centre, India
2Chemical Resources (CHERESO), India
J Clin Mol Endocrinol 2018, Volume 3
DOI: 10.21767/2572-5432-C1-003